Using SST2 And NT-proBNP Levels To Evaluate The Efficacy And Safety Of Intravenous Administration Of Recombinant Human Brain Natriuretic Peptide In Patients With Heart Failure After Acute Myocardial Infarction

Objective:To investigate the efficacy and safety of intravenous recombinant human brain natriuretic peptide in patients with heart failure after acute myocardial infarction by sST2 and NT-proBNP levels.Methods:The patients with acute myocardial infarction who were hospitalized in Shengjing Hospital affiliated to China Medical University from March 2017 to July 2017 and whose onset time was less than 12 h were enrolled.All patients underwent percutaneous coronary intervention within the effective time window.The patients were divided into rhBNP group(n=18)and routine treatment group(n=18)according to whether they were treated with recombinant human brain natriuretic peptide,thereby comparing the two groups before and after treatment the improvement of cardiac function and sST2,NT-proBNP,heart rate,serum potassium,serum creatinine recovery and major adverse cardiovascular events after 30 days.Results: In the experimental group,4 cases were effective,12 cases were moderately effective,and the total effective rate was 88.89%.In the control group,3 cases were significantly effective,7 cases were moderately effective and the total effective rate was 55.56%.The difference was statistically significant.The level of serum sST2 in the experimental group decreased by(69.33 ± 60.28)ng/mL,which was significantly lower than that in the control group(23.56 ± 55.43)ng/m L.The level of NT-proBNP in the experimental group decreased by(5628.34 ± 5996.71)pg/m L,which was significantly different from the conventional treatment group(776.11 ± 1916.17)pg/m L,P value are less than 0.05.According to the treatment effect is effective,divided into effective treatment group and ineffective treatment group,the effective treatment group decreased sST2 level(66.37 ± 57.68)ng/m L,invalid group decreased(-11.70 ± 26.67)ng/m L;NT-proBNP level effective group decreased(4298.00 ± 5238.54)pg/mL,ineffective group decreased(86.80 ± 2394.06)pg/m L,both statistically significant.There were 3 cases(16.67%)of patients with hypotension and 4 cases(22.22%)of control group,there was no significant difference between the two groups in the treatment group.The major cardiovascular adverse events,cardiogenic shock and sudden death group were not found.Conclusion:Intravenous rhBNP has obvious curative effect on patients with heart failure after acute myocardial infarction,which can be evaluated by serum sST2 level.Serum sST2 level is correlated with NT-proBNP,because of its less affected factors sST2 can be used as a new generation of heart failure markers.